Did the 2004 World Health Organization (WHO) histologic classification result in better prognostic categories for resected thymomas as compared to 1999 WHO classification scheme? This is an ASCO ...
MET amplification or overexpression is the most common “off-target” mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed ...
Building an anticancer strategy takes time and the history of anti-HER drugs development reflects the challenge that each new molecular marker faces until the approval of a targeted therapy for ...
Cohort 1, osimertinib monotherapy. Cohort 2, a combination of osimertinib and savolitinib therapy. The cutoff date: May 28, 2024. FAS, Full Analysis Set; PD, Progressive disease. [1] Patients with MET ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS ...
Rybrevant Faspro is a new under-the-skin (subcutaneous) injection form of the cancer medicine Rybrevant (amivantamab). The FDA has now approved it in combination with another medicine called ...
Lung cancer is the leading cause of cancer deaths globally. Many cases are driven by mutations in the EGFR gene, which causes cells to grow and divide uncontrollably. In Southeast Asia, these ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
What Is It, and Why Does It Matter? Rybrevant Faspro is an under-the-skin (subcutaneous, or SC) injection form of the anticancer medicine Rybrevant (amivantamab). The FDA has approved a new monthly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results